Trial Profile
A Phase 1, Open-Label, Multiple Ascending Dose, [18F]MNI-659 PET-Imaging Study to Evaluate PDE10A Occupancy After Dosing With EVP-6308 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs FRM 6308 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors FORUM Pharmaceuticals
- 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 09 Dec 2013 Status changed from planning to recruiting, as reported by ClinicalTrials.gov record record.
- 09 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.